2/28
06:11 pm
orgo
Organogenesis (ORGO) was upgraded by
Weiss Ratings from "sell (d+)" to "hold (c)".
Medium
Report
Organogenesis (ORGO) was upgraded by
Weiss Ratings from "sell (d+)" to "hold (c)".
2/27
08:02 am
orgo
Organogenesis (ORGO) had its price target lowered by BTIG Research from $9.00 to $8.00. They now have a "buy" rating on the stock.
High
Report
Organogenesis (ORGO) had its price target lowered by BTIG Research from $9.00 to $8.00. They now have a "buy" rating on the stock.
2/27
12:13 am
orgo
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... [Yahoo! Finance]
High
Report
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... [Yahoo! Finance]
2/27
12:02 am
orgo
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/26
04:05 pm
orgo
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
High
Report
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
2/19
04:44 pm
orgo
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Low
Report
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
2/19
04:05 pm
orgo
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
Low
Report
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
2/3
02:05 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/29
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/27
01:27 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/25
07:52 am
orgo
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Low
Report
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
1/22
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/20
04:11 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/15
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/13
04:07 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/8
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/6
12:49 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
1/5
08:00 am
orgo
Avista Healthcare Partners Announces Promotions
Medium
Report
Avista Healthcare Partners Announces Promotions
12/30
04:38 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
12/26
08:02 am
orgo
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
12/23
04:05 pm
orgo
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Low
Report
Organogenesis Announces Initiation of Biologics License Application for ReNu®
12/16
08:05 am
orgo
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
12/15
04:40 pm
orgo
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain [Yahoo! Finance]
Medium
Report
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain [Yahoo! Finance]
12/15
04:25 pm
orgo
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
High
Report
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
12/10
04:10 am
orgo
Organogenesis (NASDAQ:ORGO) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Organogenesis (NASDAQ:ORGO) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.